Skip to content
‹ Back to IndustriesSciences

SupplySide West 2021: Market Trends

SupplySide West 2021 serves as a critical platform for companies like Deerland to innovate and stay attuned to market trends. The event enables face-to-face interactions, allowing Deerland to engage directly with customers and industry peers. Deerland aims to expand beyond supplements into food and beverage sectors, leveraging versatile ingredient applications and exploring diverse product formats.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Diverse Delivery FormatsFood and BeverageHuman-grade IngredientsIndustry Trends.
Share
SupplySide West 2021: Market Trends

Key takeaways

01

SupplySide West provides a platform for innovation and understanding customer needs.

02

Deerland is expanding into food and beverage through versatile ingredient applications.

03

Embracing diverse delivery formats, like gummies and liquids, attracts significant interest.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Supply Side West holds immense significance for Deerland, providing a platform for innovation and a chance to understand customer needs. This event keeps Deerland in tune with market trends and ensures the development of impactful and sought-after products. The return to in-person interactions at Supply Side West is truly invigorating, allowing Deerland to engage with industry peers and customers face-to-face.

With a focus on food and beverage, Deerland aims to expand its reach beyond the supplement space. The goal is to showcase the versatility of their ingredients, probiotics, and Solarplast in diverse applications. Embracing different delivery formats is a key trend, with gummies and liquid formats gaining significant interest. By exploring new avenues outside traditional capsules, Deerland aims to meet evolving consumer preferences and offer innovative solutions.

The connection between the human and pet industries is becoming increasingly apparent. Consumers seek clean and functional ingredients that enhance the health and well-being of both themselves and their pets. Deerland already produces human-grade ingredients, aligning with the growing demand for quality in the pet industry. As the pet market evolves, new ingredients will play a crucial role. Combining probiotics with prebiotics or phages to create synergistic functional ingredients holds promise for future pet products.

Supply Side West’s incorporation of food ingredients is a welcome development, as it highlights the blending of the food and supplement sectors. Deerland has identified complementary ingredients that can enhance their flagship DE111 probiotic, such as powdered kombucha, powdered kefir, and the growing interest in hemp and botanicals. The opportunities are endless, and Supply Side West offers a diverse and vibrant environment to explore and learn from.

Attending Supply Side West for the first time has provided a fresh perspective for Deerland. Stepping out of their comfort zone and witnessing the broader industry landscape has been both insightful and enjoyable. It’s not only about understanding industry trends but also recognizing the impact that DE111, Deerland’s flagship product, is making in the market.

Deerland remains committed to staying at the forefront of innovation and responding to customer demands. By embracing new ingredients, exploring novel delivery formats, and maintaining a human-grade standard, Deerland aims to drive positive change and contribute to the well-being of people and pets alike.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

SR-Tiget gene therapy families average six months in Milan and years of lab tests

SR-Tiget gene therapy families average six months in Milan and years of lab tests

Gene therapy at Milan’s SR-Tiget includes a family support programme that helps relatives manage months-long stays (often around six months) for treatment, while a regulated lab can track patient samples for up to 20 years. Follow-up visits can outnumber new treatments, adding to the long-term workload.

  • 01In 2025, the programme logged 133 follow-up visits against 17 treatments; with roughly 15 years of twice-yearly checkups per patient, the follow-up load is likely to keep growing even if new treatments stay flat.
  • 02At SR-Tiget, the average family spends six months in Milan, and the child's samples can keep reaching the lab for as long as twenty years.
  • 03Any gene therapy service has to answer one question: who tells the lab when a child's fever pushes a blood draw from morning to afternoon? In Milan, research nurses own that handoff.

Nov 16, 2026

Two photonic AI components reach outside testers—limited access

Two photonic AI components reach outside testers—limited access

Kopin is expanding microLED manufacturing in Westborough, Massachusetts, which could add up to 80 jobs over five years. Its microLEDs will go to military displays and to Neural I/o, an interconnect that sends AI data as light. In the same news round-up, Q.ANT and IONOS opened a photonic processor pilot where approved applicants can run their own workloads.

  • 01Two photonic approaches tied to AI’s power problem reached testable hardware this month: PsiQuantum’s 8×8 optical switch samples and Q.ANT’s second-generation processor via an IONOS bare-metal pilot in Germany.
  • 02PsiQuantum is sending samples of an 8×8 demonstration optical circuit switch to selected prospective customers, giving buyers hardware they can test even though commercial products and full specs are still pending.
  • 03Staffing may not keep up with demand: a 2023 Applied Optics study projected US demand for 42,000 new middle-skilled photonics workers by 2030, and Kopin’s expansion adds another competitor for photonics technicians in Massachusetts.

Nov 15, 2026

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly breaks ground on a $5B Virginia bioconjugate plant; first building expected in 2030

Lilly’s Goochland County site is designed to make APIs and finished medicines on one campus. Virginia Business reported the first building is expected to open in 2030.

  • 01Goochland’s pilot-scale training center is slated to open in 2028, two years before Lilly expects its first production building in 2030—signaling workforce readiness as the earliest milestone at Lilly’s first dedicated, fully integrated API and drug product facility for its bioconjugate platform and monoclonal antibody portfolio.
  • 02For anyone tracking new ADC supply, Goochland is a later story: Lilly expects to open the first building in 2030 and the second in 2031.

Nov 15, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512